Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Clinical Trials

Potential treatments for macular degeneration must go through a lengthy series of human clinical trials before seeking approval by the U.S. Food and Drug Administration.

Information about clinical trials for the United States as well as clinical trials occurring globally are available at www.clinicaltrials.gov.

Our Phase I/II clinical trials started in December 2011. Learn More.


Join our mailing list and receive updated information as it becomes available:

Avalanche Biotechnologies Secures $55 Million in Oversubscribed Series B Financing

April 22, 2014

– Proceeds will Further Strengthen Avalanche’s Proprietary BioFactoryTM Platform and Advance Clinical Program in Wet Age-Related Macular Degeneration –


MENLO PARK, Calif., April 22, 2014 -- Avalanche Biotechnologies, Inc, a leader in the development of innovative gene therapies for serious eye diseases such as wet age-related macular degeneration (AMD), today announced the successful completion of a $55 million Series B financing. New investors were led by Venrock, and included Deerfield, Adage Capital Management, Redmile Group, Rock Springs Capital, Sabby Capital, as well as an affiliate of Cowen & Company and two undisclosed blue chip health care funds; joining the existing investors. Cowen & Company acted as sole placement agent for the financing.

Read More

Read All Avalanche News